ImStem Biotechnology to Launch Phase 1 Trial Testing IMS001 for MS
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the investigational new drug…
Articles by Margarida Azevedo, MSc
Second Phase 3 Trial of MedDay’s MD1003 for Progressive MS Fails to Meet Goals
MedDay Pharmaceuticals‘Â MD1003 did not ease functional disability or its progression in patients with non-active progressive…
Potential Therapy, Anavex 2-73, Shows Ability to Protect Neurons and Promote Myelin in Early Tests
Anavex Life Sciences‘ investigational therapy Anavex 2-73 (blarcamesine) showed an ability to protect, repair, and induce the formation of…
Spanish Modified Story Memory Technique Improves Cognitive Performance in Mexican Patients with MS, Study Says
The Spanish version of the modified Story Memory Technique improves learning and life satisfaction of Mexican patients with…
#CMSC16 – MS Research Highlights How Sensory Processing, Fatigue, and Cognition Assessment May Improve Clinical Care
Melissa A. Colbeck, an investigator at the Occupational Therapy, Health Sciences Centre in Winnipeg, Canada, studied how different sensory processing…
#CMSC16 – MS Care Should Include Fatigue, Sleep Quality and Inattentiveness Assessment, Study Shows
Mayis Al Dughmi, of the Physical Therapy and Rehabilitation Science at the University of Kansas Medical Center, recently presented…
#CMSC16 – Researchers Present Findings Showing Women with MS Have Significant Depression, Fatigue, Decline in Cognitive Function
Researchers at the University of Arizona studied the psychosocial symptoms felt by a group of female patients with multiple…
MS Research Australia Supporting Effort to Harness Anti-inflammatory Potential of Parasitic Worms
Researchers at the University of Technology Sydney (UTS) ithree institute are taking a novel approach in an attempt to halt disease progression in multiple…
Report Highlights Series of Changes Needed from Canadian Employers and Government to Improve MS Patients’ Lives
A new report by the Conference Board of Canada’s Canadian Alliance for Sustainable Health Care (CASHC) notes that employers and the Canadian…
Mitoxantrone, a Drug for Progressive and Severe Relapsing MS, Linked to Colorectal Cancer Risk
Mitoxantrone,  a multiple sclerosis (MS)  drug that is already associated with a higher risk for leukemia and heart damage, may also raise…
United Spinal Association Offering Range of Materials at Exhibit Booth at CMSC 2016
The United Spinal Association, a nonprofit focused on improving the quality of life for people with spinal cord injuries and disorders (SCI/D),…
Celebrate Vision Health Month by Getting Your Eyes Examined, Optometrist Group Says
The Canadian Association of Optometrists is urging people to have their eyes examined regularly as a part of their preventive care…
Opexa’s CEO Gives Update on T-Cell Therapy at Vatican Conference
Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy…
Florida Atlantic University Researcher Awarded $540K NIH Grant to Research Collagen Degradation in Diseases Like MS
A researcher at Florida Atlantic University (FAU) has been awarded a $540,250 grant from the National Cancer Institute, part of the National…
Mayo Clinic Neurologist, Creator of MS Lesion Tissue Bank, Receives 2016 John Dystel Prize for MS Research
Dr. Claudia Lucchinetti, chair of the Department of Neurology at the Mayo Clinic and the Eugene and Marcia Applebaum Professor…
Sanofi Genzyme Presenting New Data on Lemtrada’s Beneficial Effects, Drawn from RRMS Extension Study, at AAN 2016
Sanofi Genzyme is presenting promising data regarding brain volume and retinal nerve fibers in multiple sclerosis (MS) patients — drawn…
Promising Phase 1 Trial Results of Stem Cell Therapy in Progressive MS Patients Being Presented at AAN Meeting
Potentially groundbreaking research by the Tisch Multiple Sclerosis Research Center of New York (MSRCNY) will be presented on April 19 at…
Antihistamine Aids in Reversing Visual Damage in MS Patients, Appears to Have Remyelination Properties, AAN Presentation Reports
A Phase 2 clinical trial testing the efficacy of a common antihistamine, clemastine fumarate, to treat optic nerve damage in people with…
PathMaker Launches Clinical Trial of MyoRegulator to Treat Spasticity, Common in MS
PathMaker Neurosystems, Inc., recently announced the launch of an Institutional Review Board (IRB)-approved clinical trial, in partnership with Northwell Health (formerly North…
Experimental MS Oral Antibiotic Combination Therapy Showing Promise in Phase 2a Study, RedHill Biopharma Reports
RedHill Biopharma, Ltd. recently announced promising interim results from its ongoing CEASE-MS Phase 2a clinical trial evaluating the safety and efficacy…
Oral MS Drug Derived from Plant Peptide Seen to Stop Disease Progression in Mice
Researchers, working with an animal model of multiple sclerosis (MS), discovered that oral treatment with a synthesized plant peptide, known…
MS Patients Being Recruited for At-Home Study of Bacteria’s Benefits on Bladder Health
The United Spinal Association, a nonprofit focused on improving the quality of life of people with spinal cord injuries and disorders…
CONy16: MS Researchers Question Possible Long-term Benefits of Remyelination Therapies
Multiple sclerosis was a main focus at the four-day 10th World Congress on Controversies in Neurology (CONy), in Lisbon, Portugal, that concluded on…
Resistance Training in Ms Patients Found to Improve Hip Strength, Walking Ability
Researchers at the Kennedy Krieger Institute and Johns Hopkins University School of Medicine released preliminary results of an ongoing…
MS Research Australia Funds Projects into Targeted Gene Suppression, Drug Delivery
Professor Steve Wilton and Dr. Rakesh Veedu from Murdoch University’s Centre for Comparative Genomics in Western Australia received project grants…
New MS Survey Looks into Patients’ Appraisal of Risks, Benefits When Choosing Therapies
A large-scale online survey, funded by the National Multiple Sclerosis Society  and developed by researchers, is investigating how multiple sclerosis…
Kinase Inhibitor, Masitinib, Spotted for Potential to Treat Neurological Disorders Like PPMS
AB Science recently reported the publication of four peer-reviewed and independent research papers that add to the growing recognition of masitinib,…
MS Society Honors MS Awareness Week with New ‘Together We Are Stronger’ Campaign
The National Multiple Sclerosis Society launched a new awareness campaign for Multiple Sclerosis Awareness Week, which runs through March 13, featuring…
Progressive MS Clinical Trial of Rituximab Stopped After Drug Fails to Show Effectiveness
Researchers at the National Institutes of Health (NIH)Â announced that a small clinical trial of a progressive multiple sclerosis (MS)…
Therapeutic Target for Stabilizing Histamine, an Inflammatory Agent in MS, Identified in Fruit Fly Study
Researchers at the University of Massachusetts Medical School, working in the fruit fly model, identified an organic cation transporter, CarT (carcinine…